Symptoms can include itching, dryness, bumps, rash, blisters, or swelling. Contact dermatitis can occur on any part of the body, including the elbows. There are two broad categories of contact ...

Doctors are urging people not to ignore the symptoms of scabies because of the perceived social stigma attached to having the condition as cases rise in England. Some 3,689 cases of the highly ...

This Victorian-era disease is caused by tiny mites that burrow into the skin, causing itching and a rash that usually spreads across the whole body. The rash can affect any part of the body ...

Cases of highly infectious skin bug scabies are surging across the UK, with cases occurring 'out of nowhere' and whole households affected. The condition, caused by microscopic mites that burrow ...

Roche is looking to use Dyno’s technologies to target neurological diseases, a big focus at the Swiss pharma, with multiple sclerosis blockbuster Ocrevus serving as its best-selling asset.

People are being told not to ignore an itchy rash, with GPs in England reporting a spike in scabies - the highly infectious skin infestation. The condition is caused by a mite which burrows under ...

Scabies can lead to secondary skin infections, if not treated. People are being told not to ignore an itchy rash, with GPs in England reporting a spike in scabies - the highly infectious skin ...

Roche’s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs. Sales of Vabysmo, an age-related macular degeneration (AMD) treatment ...

In September, the Swiss pharma won back-to-back FDA approvals for subcutaneous versions of its multiple sclerosis drug Ocrevus and cancer immunotherapy Tecentriq. Dubbed Ocrevus Zunovo ...

While pricing power and demand for Biogen's injectable MS portfolio are eroding in the face of new competition, Biogen receives substantial royalties on Roche's popular drug Ocrevus, which helps ...

Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo Therapeutics, UCB and Catalent that you may have missed. MacroGenics, a developer of antibody medicines for ...